Advertisement
UK markets close in 3 hours 38 minutes
  • FTSE 100

    8,117.10
    +38.24 (+0.47%)
     
  • FTSE 250

    19,817.79
    +215.81 (+1.10%)
     
  • AIM

    755.38
    +2.26 (+0.30%)
     
  • GBP/EUR

    1.1666
    +0.0009 (+0.08%)
     
  • GBP/USD

    1.2512
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    51,310.31
    +191.16 (+0.37%)
     
  • CMC Crypto 200

    1,385.00
    -11.54 (-0.83%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    84.09
    +0.52 (+0.62%)
     
  • GOLD FUTURES

    2,357.50
    +15.00 (+0.64%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,052.96
    +135.68 (+0.76%)
     
  • CAC 40

    8,039.98
    +23.33 (+0.29%)
     

Pfizer and Sangamo Therapeutics: Hemophilia A Gene Therapy

Pfizer and Sangamo Therapeutics: Hemophilia A Gene Therapy

In May 2017, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced a collaboration for hemophilia A gene therapy that includes SB-525, which is one of Sangamo Therapeutics’ four lead product candidates. This collaboration is highly synergistic, as it combines Pfizer’s expertise in rare diseases with Sangamo Therapeutics’ expertise in genomic therapies.